title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
Is it a Good Idea to Invest in AC Immune  ( ACIU )  Stock Now?,20231205T105900,https://www.zacks.com/stock/news/2193345/is-it-a-good-idea-to-invest-in-ac-immune-aciu-stock-now,CTMX,0.282234,Neutral,0.14456
Stocks That Hit 52-Week Lows On Friday,20220506T160650,https://www.benzinga.com/markets/options/22/05/27050916/52-weeks-high-and-low-article,CTMX,0.005467,Neutral,0.005629
Stocks That Hit 52-Week Lows On Thursday,20220428T193101,https://www.benzinga.com/markets/options/22/04/26872967/52-weeks-high-and-low-article,CTMX,0.00644,Neutral,0.000103
Stocks That Hit 52-Week Lows On Monday,20220418T154044,https://www.benzinga.com/news/22/04/26669813/stocks-that-hit-52-week-lows-on-monday,CTMX,0.005428,Neutral,0.022374
Stocks That Hit 52-Week Lows On Monday,20220328T154408,https://www.benzinga.com/news/22/03/26326033/stocks-that-hit-52-week-lows-on-monday,CTMX,0.016131,Neutral,-0.017216
Stocks That Hit 52-Week Lows On Wednesday,20220323T154749,https://www.benzinga.com/news/22/03/26261101/stocks-that-hit-52-week-lows-on-wednesday,CTMX,0.03456,Neutral,-0.041653
Stocks That Hit 52-Week Lows On Wednesday,20220427T184104,https://www.benzinga.com/markets/options/22/04/26844275/52-weeks-high-and-low-article,CTMX,0.006956,Neutral,0.011154
"Pyxis Oncology Reports Financial Results for the Second Quarter Ended June 30, 2022 and Provides Pipeline Update",20220815T110000,https://www.globenewswire.com/news-release/2022/08/15/2498065/0/en/Pyxis-Oncology-Reports-Financial-Results-for-the-Second-Quarter-Ended-June-30-2022-and-Provides-Pipeline-Update.html,CTMX,0.024597,Neutral,-0.011764
Stocks That Hit 52-Week Lows On Thursday,20220421T175401,https://www.benzinga.com/markets/options/22/04/26742233/52-weeks-high-and-low-article,CTMX,0.021637,Bearish,-0.431235
Stocks That Hit 52-Week Lows On Monday,20220314T161153,https://www.benzinga.com/news/22/03/26125409/stocks-that-hit-52-week-lows-on-monday,CTMX,0.003772,Neutral,-0.018437
Stocks That Hit 52-Week Lows On Thursday,20220526T161527,https://www.benzinga.com/markets/options/22/05/27422270/52-weeks-high-and-low-article,CTMX,0.048646,Neutral,0.00015
Ligand  ( LGND )  Up 9% on FDA Nod for Molluscum Infection Gel,20240108T174700,https://www.zacks.com/stock/news/2207168/ligand-lgnd-up-9-on-fda-nod-for-molluscum-infection-gel,CTMX,0.387875,Neutral,-0.035141
Allogene  ( ALLO )  Down 20% on Strategic Changes in Pipeline,20240105T175200,https://www.zacks.com/stock/news/2206512/allogene-allo-down-20-on-strategic-changes-in-pipeline,CTMX,0.22616,Neutral,0.05996
Esperion  ( ESPR )  Settles Milestone Dispute With Daiichi Sankyo,20240104T160800,https://www.zacks.com/stock/news/2205756/esperion-espr-settles-milestone-dispute-with-daiichi-sankyo,CTMX,0.295155,Neutral,0.074228
Stocks That Hit 52-Week Lows On Wednesday,20220504T162909,https://www.benzinga.com/markets/options/22/05/26995541/52-weeks-high-and-low-article,CTMX,0.012359,Neutral,0.007131
CD3 Antibody Clinical Trials Market Opportunity Insight,20231012T062602,https://www.benzinga.com/pressreleases/23/10/g35212251/cd3-antibody-clinical-trials-market-opportunity-insight,CTMX,0.047278,Somewhat-Bullish,0.188605
Here's Why You Should Add ImmunoGen  ( IMGN )  to Your Portfolio Now,20230519T150900,https://www.zacks.com/stock/news/2097447/heres-why-you-should-add-immunogen-imgn-to-your-portfolio-now,CTMX,0.145583,Neutral,0.002652
Stocks That Hit 52-Week Lows On Friday,20220422T162629,https://www.benzinga.com/markets/options/22/04/26764450/52-weeks-high-and-low-article,CTMX,0.012589,Neutral,0.0058
"Why FreightCar America Shares Are Trading Lower By 8%; Here Are 20 Stocks Moving Premarket - Accelerate Diagnostics  ( NASDAQ:AXDX ) , Biodexa Pharmaceuticals  ( NASDAQ:BDRX ) ",20230328T123341,https://www.benzinga.com/news/23/03/31528044/why-freightcar-america-shares-are-trading-lower-by-8-here-are-20-stocks-moving-premarket,CTMX,0.146916,Somewhat-Bearish,-0.188406
"Dow Jumps 700 Points; S&P 500 Rises Over 2% - Aehr Test Systems  ( NASDAQ:AEHR ) , ATAI Life Sciences  ( NASDAQ:ATAI ) ",20230106T194324,https://www.benzinga.com/news/earnings/23/01/30316154/dow-jumps-700-points-s-p-500-rises-over-2,CTMX,0.104911,Somewhat-Bullish,0.196989
"Nasdaq Gains 1.5%; Fate Therapeutics Shares Plunge - Aehr Test Systems  ( NASDAQ:AEHR ) , ATAI Life Sciences  ( NASDAQ:ATAI ) ",20230106T170106,https://www.benzinga.com/news/earnings/23/01/30313745/nasdaq-gains-1-5-fate-therapeutics-shares-plunge,CTMX,0.10607,Somewhat-Bullish,0.197681
"Why Graphite Bio Shares Are Trading Lower By 50%; Here Are 20 Stocks Moving Premarket - ABVC BioPharma  ( NASDAQ:ABVC ) , Acasti Pharma  ( NASDAQ:ACST ) ",20230106T130036,https://www.benzinga.com/news/23/01/30309039/why-graphite-bio-shares-are-trading-lower-by-50-here-are-20-stocks-moving-premarket,CTMX,0.127119,Neutral,0.0
Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket - AppLovin  ( NASDAQ:APP ) ,20240509T121328,https://www.benzinga.com/news/24/05/38729362/why-applovin-shares-are-trading-higher-by-15-here-are-20-stocks-moving-premarket,CTMX,0.12645,Neutral,0.129989
" ( AHI ) ,  ( ALNA )  - Why DWAC Is Trading Lower By Around 19%; Here Are 32 Stocks Moving Premarket",20220906T104131,https://www.benzinga.com/news/22/09/28752577/why-dwac-is-trading-lower-by-around-19-here-are-32-stocks-moving-premarket,CTMX,0.170878,Neutral,-0.005868
"CytomX Therapeutics  ( CTMX )  Reports Q2 Loss, Lags Revenue Estimates",20220804T214514,https://www.zacks.com/stock/news/1964263/cytomx-therapeutics-ctmx-reports-q2-loss-lags-revenue-estimates,CTMX,0.397098,Neutral,0.079507
Here's Why Arcutis Stock More Than Doubled in Market Value in One Year,20250103T182800,https://www.zacks.com/stock/news/2391837/heres-why-arcutis-stock-more-than-doubled-in-market-value-in-one-year,CTMX,0.282234,Neutral,0.046443
MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug,20250103T155600,https://www.zacks.com/stock/news/2391722/meso-stock-surges-80-in-a-month-after-fda-approval-of-gvhd-drug,CTMX,0.262805,Neutral,0.009964
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA,20250103T152300,https://www.zacks.com/stock/news/2391709/capr-stock-up-on-completion-of-rolling-submission-of-dmd-drug-bla,CTMX,0.220008,Neutral,0.008626
Neumora Stock Hits Record Low on Depression Drug Study Failure,20250103T141400,https://www.zacks.com/stock/news/2391560/neumora-stock-hits-record-low-on-depression-drug-study-failure,CTMX,0.215894,Neutral,0.037466
PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?,20250102T182800,https://www.zacks.com/stock/news/2391214/pgen-stock-surges-more-than-40-in-a-week-whats-driving-the-rally,CTMX,0.185781,Neutral,0.041291
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag,20250102T145600,https://www.zacks.com/stock/news/2390869/vstm-up-as-nda-for-ovarian-cancer-combo-gets-fdas-priority-review-tag,CTMX,0.242406,Neutral,0.009323
JNJ Inks Licensing Deal With Kaken for Eczema Candidate KP-723,20241227T121700,https://www.zacks.com/stock/news/2388625/jnj-inks-licensing-deal-with-kaken-for-eczema-candidate-kp-723,CTMX,0.244109,Neutral,0.007533
MindMed Stock Skyrockets 94% Year to Date: What's Driving It?,20241224T152500,https://www.zacks.com/stock/news/2387577/mindmed-stock-skyrockets-94-year-to-date-whats-driving-it,CTMX,0.237551,Neutral,0.031344
Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek,20241223T184400,https://www.zacks.com/stock/news/2387103/vertex-secures-fda-approval-for-new-cystic-fibrosis-drug-alyftrek,CTMX,0.165788,Neutral,0.038087
AZN's Tagrisso Gets Approval in the EU for Expanded Use in NSCLC,20241223T155600,https://www.zacks.com/stock/news/2386987/azns-tagrisso-gets-approval-in-the-eu-for-expanded-use-in-nsclc,CTMX,0.229149,Neutral,0.00716
RARE Submits BLA to the FDA for Sanfilippo Syndrome Gene Therapy,20241220T162700,https://www.zacks.com/stock/news/2386436/rare-submits-bla-to-the-fda-for-sanfilippo-syndrome-gene-therapy,CTMX,0.150827,Neutral,0.005273
VRTX Down as Non-Opioid Drug Shows Similar Pain Reduction as Placebo,20241220T161300,https://www.zacks.com/stock/news/2386433/vrtx-down-as-non-opioid-drug-shows-similar-pain-reduction-as-placebo,CTMX,0.232996,Neutral,0.032809
KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707,20241219T160800,https://www.zacks.com/stock/news/2385855/krys-reports-upbeat-initial-data-from-lung-cancer-study-of-kb707,CTMX,0.215415,Neutral,0.006817
SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder,20241219T134500,https://www.zacks.com/stock/news/2385698/srpt-finishes-enrolment-in-late-stage-study-for-rare-muscular-disorder,CTMX,0.175433,Neutral,0.039606
GILD's Trodelvy Gets Second Breakthrough Therapy Tag for Lung Cancer,20241218T151400,https://www.zacks.com/stock/news/2385341/gilds-trodelvy-gets-second-breakthrough-therapy-tag-for-lung-cancer,CTMX,0.179454,Neutral,0.007413
EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study,20241217T141800,https://www.zacks.com/stock/news/2384502/ewtx-stock-rises-on-upbeat-data-from-rare-muscular-disorder-study,CTMX,0.204503,Neutral,0.008189
Merck Ends Development of Two Experimental Cancer Drugs,20241217T140300,https://www.zacks.com/stock/news/2384462/merck-ends-development-of-two-experimental-cancer-drugs,CTMX,0.206245,Neutral,0.008243
CHMP Endorses Merck's Kidney Cancer Drug for Two Indications,20241216T155700,https://www.zacks.com/stock/news/2384062/chmp-endorses-mercks-kidney-cancer-drug-for-two-indications,CTMX,0.219312,Neutral,0.008657
"EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce",20241216T154300,https://www.zacks.com/stock/news/2384053/edit-stock-falls-on-decision-to-end-reni-cel-studies-cut-workforce,CTMX,0.187827,Neutral,0.006135
"CytomX Therapeutics  ( CTMX )  May Find a Bottom Soon, Here's Why You Should Buy the Stock Now",20241216T145507,https://www.zacks.com/stock/news/2383973/cytomx-therapeutics-ctmx-may-find-a-bottom-soon-heres-why-you-should-buy-the-stock-now,CTMX,0.405651,Bullish,0.425337
ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline,20241216T144200,https://www.zacks.com/stock/news/2383942/abbv-to-acquire-nimble-therapeutics-to-strengthen-immunology-pipeline,CTMX,0.208017,Neutral,0.006632
KRYS Stock Down on Initial Clinical Updates on KB407 & KB408,20241213T160800,https://www.zacks.com/stock/news/2383462/krys-stock-down-on-initial-clinical-updates-on-kb407-kb408,CTMX,0.220809,Neutral,0.031436
SNY's Tolebrutinib Gets FDA Breakthrough Therapy Tag for nrSPMS,20241213T155800,https://www.zacks.com/stock/news/2383449/snys-tolebrutinib-gets-fda-breakthrough-therapy-tag-for-nrspms,CTMX,0.253646,Neutral,0.035122
NVO Gets Positive CHMP Opinion in EU for Ozempic Expanded Use in CKD,20241213T134800,https://www.zacks.com/stock/news/2383219/nvo-gets-positive-chmp-opinion-in-eu-for-ozempic-expanded-use-in-ckd,CTMX,0.158259,Neutral,0.006801
Here's Why Q32 Bio Stock Hit a New Record Low on Wednesday,20241212T160000,https://www.zacks.com/stock/news/2382902/heres-why-q32-bio-stock-hit-a-new-record-low-on-wednesday,CTMX,0.246582,Neutral,0.009508
Here's Why Agios Stock Plummeted More Than 20% on Monday,20241210T154600,https://www.zacks.com/stock/news/2381632/heres-why-agios-stock-plummeted-more-than-20-on-monday,CTMX,0.215415,Neutral,0.008564
AbbVie's Recently Acquired Parkinson's Drug Meets Third Study Goal,20241210T153900,https://www.zacks.com/stock/news/2381629/abbvies-recently-acquired-parkinsons-drug-meets-third-study-goal,CTMX,0.220308,Neutral,0.008688
Grifols Stock Declines After Brookfield Drops Buyout Offer,20241128T150200,https://www.zacks.com/stock/news/2376569/grifols-stock-declines-after-brookfield-drops-buyout-offer,CTMX,0.304679,Neutral,0.0429
CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20241127T130000,https://www.benzinga.com/pressreleases/24/11/g42212288/cytomx-therapeutics-to-present-at-the-36th-annual-piper-sandler-healthcare-conference,CTMX,0.259267,Neutral,0.063415
CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference,20241127T130000,https://www.globenewswire.com/news-release/2024/11/27/2988176/37704/en/CytomX-Therapeutics-to-Present-at-the-36th-Annual-Piper-Sandler-Healthcare-Conference.html,CTMX,0.210274,Neutral,0.0
AstraZeneca's Combination Therapy Meets Goal in Prostate Cancer Study,20241126T191800,https://www.zacks.com/stock/news/2375636/astrazenecas-combination-therapy-meets-goal-in-prostate-cancer-study,CTMX,0.321393,Neutral,0.049535
JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer,20241121T170800,https://www.zacks.com/stock/news/2373587/jazz-secures-fda-approval-for-ziihera-in-biliary-tract-cancer,CTMX,0.354572,Neutral,0.048186
"Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%",20241120T143000,https://www.zacks.com/stock/news/2372720/grifols-board-rejects-brookfields-buyout-offer-stock-down-8,CTMX,0.343755,Neutral,0.047079
"Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics  ( CTMX )  Looks Ripe for a Turnaround",20241119T143507,https://www.zacks.com/stock/news/2372121/down--2559-in-4-weeks-heres-why-cytomx-therapeutics-ctmx-looks-ripe-for-a-turnaround,CTMX,0.493128,Somewhat-Bullish,0.212655
CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC,20241119T132300,https://www.zacks.com/stock/news/2371987/chmp-endorses-astrazenecas-tagrisso-for-expanded-use-in-nsclc,CTMX,0.327366,Neutral,0.045361
CytomX Therapeutics  ( CTMX )  Q3 Earnings and Revenues Top Estimates,20241107T225509,https://www.zacks.com/stock/news/2366870/cytomx-therapeutics-ctmx-q3-earnings-and-revenues-top-estimates,CTMX,0.395012,Neutral,0.1156
"CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024 - CytomX Therapeutics  ( NASDAQ:CTMX ) ",20241031T120000,https://www.benzinga.com/pressreleases/24/10/g41650384/cytomx-therapeutics-to-report-third-quarter-2024-financial-results-on-november-7-2024,CTMX,0.263942,Neutral,0.074256
"Day One Biopharmaceuticals, Inc.  ( DAWN )  Surpasses Q3 Earnings and Revenue Estimates",20241030T212013,https://www.zacks.com/stock/news/2361062/day-one-biopharmaceuticals-inc-dawn-surpasses-q3-earnings-and-revenue-estimates,CTMX,0.20997,Neutral,0.0
"CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors",20240909T120000,https://www.globenewswire.com/news-release/2024/09/09/2942754/37704/en/CytomX-Therapeutics-Announces-First-Patient-Dosed-with-CX-801-a-Dually-Masked-Interferon-Alpha-2b-PROBODY-in-a-Phase-1-Study-in-Patients-with-Solid-Tumors.html,CTMX,0.195498,Neutral,0.045242
CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference,20240618T120000,https://www.globenewswire.com/news-release/2024/06/18/2900339/37704/en/CytomX-Therapeutics-to-Present-at-the-H-C-Wainwright-2nd-Annual-Immune-Cell-Engager-Virtual-Conference.html,CTMX,0.217834,Neutral,0.115574
"CytomX Therapeutics  ( NASDAQ:CTMX )  Lowered to ""Hold"" at StockNews.com",20240618T065241,https://www.defenseworld.net/2024/06/18/cytomx-therapeutics-nasdaqctmx-lowered-to-hold-at-stocknews-com.html,CTMX,0.871234,Bullish,0.414366
CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20240617T201500,https://www.benzinga.com/pressreleases/24/06/g39366109/cytomx-therapeutics-promotes-chris-ogden-to-chief-financial-officer,CTMX,0.1692,Neutral,0.038735
CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer,20240617T201500,https://www.globenewswire.com/news-release/2024/06/17/2900015/37704/en/CytomX-Therapeutics-Promotes-Chris-Ogden-to-Chief-Financial-Officer.html,CTMX,0.143629,Neutral,0.076539
 ( CTMX )  - Analyzing CytomX Therapeutics's Short Interest - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20240605T170025,https://www.benzinga.com/insights/short-sellers/24/06/39190059/ctmx-analyzing-cytomx-therapeuticss-short-interest,CTMX,0.209365,Neutral,0.148634
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference,20240522T200500,https://www.globenewswire.com/news-release/2024/05/22/2886834/37704/en/CytomX-Therapeutics-to-Present-at-the-Jefferies-Global-Healthcare-Conference.html,CTMX,0.224903,Neutral,0.0
CytomX Therapeutics Announces New Employment Inducement Grants,20240516T201500,https://www.globenewswire.com/news-release/2024/05/16/2883880/37704/en/CytomX-Therapeutics-Announces-New-Employment-Inducement-Grants.html,CTMX,0.288893,Somewhat-Bullish,0.210473
"CytomX Therapeutics  ( NASDAQ:CTMX )  Upgraded to ""Buy"" by StockNews.com",20240512T072446,https://www.defenseworld.net/2024/05/12/cytomx-therapeutics-nasdaqctmx-upgraded-to-buy-by-stocknews-com.html,CTMX,0.83383,Bullish,0.490815
What's Going On With CytomX Therapeutics Stock On Thursday? - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20240509T185921,https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38741805/analysts-varied-perspectives-on-cytomxs-cx-904-cancer-study-safety-profile-but-caut,CTMX,0.410505,Bullish,0.419724
Gold Moves Higher; Roblox Issues Weak Outlook - Roblox  ( NYSE:RBLX ) ,20240509T183025,https://www.benzinga.com/news/earnings/24/05/38741293/gold-moves-higher-roblox-issues-weak-outlook,CTMX,0.130926,Neutral,0.121721
Dow Jumps Over 150 Points; US Foods Posts Upbeat Earnings - US Foods Hldg  ( NYSE:USFD ) ,20240509T160129,https://www.benzinga.com/news/earnings/24/05/38737341/dow-jumps-over-150-points-us-foods-posts-upbeat-earnings,CTMX,0.137671,Neutral,0.125006
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20240508T201000,https://www.benzinga.com/pressreleases/24/05/g38712713/cytomx-therapeutics-reports-first-quarter-2024-financial-results-and-provides-business-update,CTMX,0.076847,Neutral,0.023608
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA®  ( pembrolizumab ) ,20240507T201500,https://www.globenewswire.com/news-release/2024/05/07/2877258/37704/en/CytomX-Therapeutics-Announces-Clinical-Collaboration-with-Merck-to-Evaluate-CX-801-in-Combination-with-KEYTRUDA-pembrolizumab.html,CTMX,0.195814,Neutral,0.049293
"Etsy Reports Downbeat Earnings, Joins Fastly, DoorDash And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Etsy  ( NASDAQ:ETSY ) , Fastly  ( NYSE:FSLY ) , DoorDash  ( NASDAQ:DASH ) ",20240502T121725,https://www.benzinga.com/news/24/05/38580803/etsy-reports-downbeat-earnings-joins-fastly-doordash-and-other-big-stocks-moving-lower-in-thursdays,CTMX,0.167322,Neutral,-0.078018
CytomX Therapeutics  ( CTMX )  Surges 214.7%: Is This an Indication of Further Gains?,20240502T120800,https://www.zacks.com/stock/news/2266699/cytomx-therapeutics-ctmx-surges-2147-is-this-an-indication-of-further-gains,CTMX,0.53784,Somewhat-Bullish,0.164934
"Why Aspen Aerogels Shares Are Trading Higher By 26%; Here Are 20 Stocks Moving Premarket - Aptevo Therapeutics  ( NASDAQ:APVO ) , Aspen Aerogels  ( NYSE:ASPN ) ",20240502T094331,https://www.benzinga.com/news/24/05/38575263/why-aspen-aerogels-shares-are-trading-higher-by-26-here-are-20-stocks-moving-premarket,CTMX,0.2035,Neutral,-0.029119
Dow Jumps 200 Points Following Fed Decision; Pfizer Earnings Top Estimates - Pfizer  ( NYSE:PFE ) ,20240501T183212,https://www.benzinga.com/news/earnings/24/05/38561882/dow-jumps-200-points-following-fed-decision-pfizer-earnings-top-estimates,CTMX,0.136499,Neutral,0.074447
"Crude Oil Down 3%; ISM Manufacturing PMI Falls In April - CytomX Therapeutics  ( NASDAQ:CTMX ) , Cemtrex  ( NASDAQ:CETX ) ",20240501T161704,https://www.benzinga.com/news/earnings/24/05/38558157/crude-oil-down-3-ism-manufacturing-pmi-falls-in-april,CTMX,0.236588,Neutral,0.012879
What's Going On With CytomX Stock? - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20240501T160518,https://www.benzinga.com/news/24/05/38557651/whats-going-on-with-cytomx-stock,CTMX,0.497391,Bullish,0.490262
US Stocks Mixed; Amazon Posts Upbeat Earnings - Amazon.com  ( NASDAQ:AMZN ) ,20240501T135159,https://www.benzinga.com/news/earnings/24/05/38552235/us-stocks-mixed-amazon-posts-upbeat-earnings,CTMX,0.22421,Neutral,0.012338
Vanda  ( VNDA )  to Report Q1 Earnings: What's in the Cards?,20240424T175800,https://www.zacks.com/stock/news/2261585/vanda-vnda-to-report-q1-earnings-whats-in-the-cards,CTMX,0.190793,Neutral,-0.003041
StockNews.com Lowers CytomX Therapeutics  ( NASDAQ:CTMX )  to Hold,20240424T082242,https://www.defenseworld.net/2024/04/24/stocknews-com-lowers-cytomx-therapeutics-nasdaqctmx-to-hold.html,CTMX,0.745397,Bullish,0.478671
GSK Gears Up for Q1 Earnings: Here's What to Expect,20240423T171600,https://www.zacks.com/stock/news/2260559/gsk-gears-up-for-q1-earnings-heres-what-to-expect,CTMX,0.193078,Neutral,-0.003069
Incyte  ( INCY )  to Report Q1 Earnings: What's in the Cards?,20240423T134400,https://www.zacks.com/stock/news/2260352/incyte-incy-to-report-q1-earnings-whats-in-the-cards,CTMX,0.185662,Neutral,0.058551
AbbVie  ( ABBV )  to Report Q1 Earnings: What's in the Cards?,20240422T165600,https://www.zacks.com/stock/news/2259539/abbvie-abbv-to-report-q1-earnings-whats-in-the-cards,CTMX,0.198628,Neutral,-0.003136
Viking  ( VKTX )  to Report Q1 Earnings: What's in the Cards?,20240419T151600,https://www.zacks.com/stock/news/2258702/viking-vktx-to-report-q1-earnings-whats-in-the-cards,CTMX,0.202366,Neutral,-0.003181
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific  ( TCB )  Collaboration with Astellas,20240403T120000,https://www.globenewswire.com/news-release/2024/04/03/2856845/37704/en/CytomX-Therapeutics-Announces-Nomination-of-Second-Clinical-Candidate-in-Broad-PROBODY-T-Cell-Engaging-Bispecific-TCB-Collaboration-with-Astellas.html,CTMX,0.119038,Neutral,0.072062
Why Oracle Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - Oracle  ( NYSE:ORCL ) ,20240312T121102,https://www.benzinga.com/news/24/03/37613941/why-oracle-shares-are-trading-higher-by-around-13-here-are-20-stocks-moving-premarket,CTMX,0.140896,Somewhat-Bullish,0.19021
CytomX Therapeutics  ( CTMX )  Lags Q4 Earnings Estimates,20240311T212003,https://www.zacks.com/stock/news/2238863/cytomx-therapeutics-ctmx-lags-q4-earnings-estimates,CTMX,0.400265,Somewhat-Bullish,0.187726
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20240311T201000,https://www.benzinga.com/pressreleases/24/03/g37598795/cytomx-therapeutics-reports-2023-financial-results-and-provides-business-update,CTMX,0.079287,Neutral,0.024774
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update,20240311T201000,https://www.globenewswire.com/news-release/2024/03/11/2844158/37704/en/CytomX-Therapeutics-Reports-2023-Financial-Results-and-Provides-Business-Update.html,CTMX,0.063678,Neutral,0.0
"Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate  ( ADC )  Toolkit - Akari Therapeutics  ( NASDAQ:AKTX ) , Peak Bio  ( OTC:PKBO ) ",20240305T130000,https://www.benzinga.com/pressreleases/24/03/g37479142/akari-therapeutics-and-peak-bio-announce-definitive-agreement-to-merge-as-equals-creating-an-expan,CTMX,0.012875,Neutral,0.0
"Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate  ( ADC )  Toolkit - Akari Therapeutics  ( NASDAQ:AKTX ) , Peak Bio  ( OTC:PKBO ) ",20240305T130000,https://www.benzinga.com/pressreleases/24/03/g37479163/akari-therapeutics-and-peak-bio-announce-definitive-agreement-to-merge-as-equals-creating-an-expan,CTMX,0.012869,Neutral,0.0
Longtime Gilead Commercial Executive Joins IntegriChain as Chairman of the Board,20240228T150000,https://www.prnewswire.com/news-releases/longtime-gilead-commercial-executive-joins-integrichain-as-chairman-of-the-board-302073845.html,CTMX,0.05749,Neutral,0.04899
CytomX  ( CTMX )  to Report Q4 Earnings: Here's What to Expect,20240227T165200,https://www.zacks.com/stock/news/2232603/cytomx-ctmx-to-report-q4-earnings-heres-what-to-expect,CTMX,0.355588,Neutral,-0.141497
AstraZeneca's  ( AZN )  sBLA for Enhertu Gets FDA's Priority Tag,20240130T124400,https://www.zacks.com/stock/news/2217677/astrazenecas-azn-sbla-for-enhertu-gets-fdas-priority-tag,CTMX,0.213517,Neutral,0.018579
Apellis  ( APLS )  Down on Negative CHMP Opinion for Pegcetacoplan,20240129T134800,https://www.zacks.com/stock/news/2216945/apellis-apls-down-on-negative-chmp-opinion-for-pegcetacoplan,CTMX,0.159218,Neutral,0.02037
SpringWorks  ( SWTX )  Surges More Than 80% in 3 Months: Here's Why,20240125T141900,https://www.zacks.com/stock/news/2215721/springworks-swtx-surges-more-than-80-in-3-months-heres-why,CTMX,0.397098,Neutral,0.032991
Heron  ( HRTX )  Gains 19% on FDA Nod for Zynrelef Label Expansion,20240125T114400,https://www.zacks.com/stock/news/2215517/heron-hrtx-gains-19-on-fda-nod-for-zynrelef-label-expansion,CTMX,0.222327,Neutral,0.02092
Jasper Therapeutics  ( JSPR )  Surges 110% in a Month: Here's Why,20240124T171400,https://www.zacks.com/stock/news/2215186/jasper-therapeutics-jspr-surges-110-in-a-month-heres-why,CTMX,0.249361,Neutral,-0.020937
Travere  ( TVTX )  Stock Up More Than 30% in 3 Months: Here's Why,20240124T162500,https://www.zacks.com/stock/news/2215121/travere-tvtx-stock-up-more-than-30-in-3-months-heres-why,CTMX,0.359014,Neutral,0.033207
Here's Why Investors May Bet on BioMarin  ( BMRN )  Stock Now,20240124T162100,https://www.zacks.com/stock/news/2215118/heres-why-investors-may-bet-on-biomarin-bmrn-stock-now,CTMX,0.294093,Neutral,-0.0283
Unicycive  ( UNCY )  Up on Positive Hyperphosphatemia Study Update,20240124T143900,https://www.zacks.com/stock/news/2214931/unicycive-uncy-up-on-positive-hyperphosphatemia-study-update,CTMX,0.217346,Neutral,0.018818
Inhibrx  ( INBX )  Up 6% on Sale of Rare Disease Drug to Sanofi,20240123T193000,https://www.zacks.com/stock/news/2214518/inhibrx-inbx-up-6-on-sale-of-rare-disease-drug-to-sanofi,CTMX,0.279015,Neutral,-0.022981
Ionis'  ( IONS )  Donidalorsen Meets Late-Stage HAE Study Goal,20240123T182300,https://www.zacks.com/stock/news/2214493/ionis-ions-donidalorsen-meets-late-stage-hae-study-goal,CTMX,0.245835,Neutral,0.01332
Lisata  ( LSTA )  Stock Up More Than 35% in 3 Months: Here's Why,20240123T171200,https://www.zacks.com/stock/news/2214420/lisata-lsta-stock-up-more-than-35-in-3-months-heres-why,CTMX,0.398148,Neutral,0.033052
Mirum  ( MIRM )  Banks on Livmarli Sales Despite Recent Setback,20240123T164400,https://www.zacks.com/stock/news/2214378/mirum-mirm-banks-on-livmarli-sales-despite-recent-setback,CTMX,0.308891,Neutral,0.027332
AstraZeneca's  ( AZN )  Imfinzi Combo Meets Liver Cancer Study Goal,20240122T194200,https://www.zacks.com/stock/news/2213719/astrazenecas-azn-imfinzi-combo-meets-liver-cancer-study-goal,CTMX,0.234458,Neutral,-0.018104
Edgewise  ( EWTX )  Rallies 35% on Issue of New Common Stock,20240122T190600,https://www.zacks.com/stock/news/2213712/edgewise-ewtx-rallies-35-on-issue-of-new-common-stock,CTMX,0.265089,Neutral,-0.021985
Alvotech  ( ALVO )  Up on BLA Update for Two Biosimilar Candidates,20240122T150300,https://www.zacks.com/stock/news/2213525/alvotech-alvo-up-on-bla-update-for-two-biosimilar-candidates,CTMX,0.43852,Neutral,0.038341
TransCode  ( RNAZ )  Down 50% on Issue of New Common Stock,20240119T180900,https://www.zacks.com/stock/news/2213010/transcode-rnaz-down-50-on-issue-of-new-common-stock,CTMX,0.291644,Neutral,-0.023738
ADC Therapeutics  ( ADCT )  Rises 43% in a Month: Here's Why,20240119T180500,https://www.zacks.com/stock/news/2213007/adc-therapeutics-adct-rises-43-in-a-month-heres-why,CTMX,0.253514,Neutral,-0.021218
Mesoblast  ( MESO )  Up on Rare Pediatric Disease Tag for Heart Drug,20240119T163000,https://www.zacks.com/stock/news/2212927/mesoblast-meso-up-on-rare-pediatric-disease-tag-for-heart-drug,CTMX,0.427425,Neutral,0.037598
Syros  ( SYRS )  Stock Surges 200% in 3 Months: Here's Why,20240119T154300,https://www.zacks.com/stock/news/2212898/syros-syrs-stock-surges-200-in-3-months-heres-why,CTMX,0.404563,Neutral,0.036199
Is ADC Therapeutics  ( ADCT )  Outperforming Other Medical Stocks This Year?,20240119T144003,https://www.zacks.com/stock/news/2212816/is-adc-therapeutics-adct-outperforming-other-medical-stocks-this-year,CTMX,0.483888,Somewhat-Bullish,0.236759
MAIA Soars 20% on Interim Results From Lung Cancer Study,20240118T180600,https://www.zacks.com/stock/news/2212386/maia-soars-20-on-interim-results-from-lung-cancer-study,CTMX,0.300946,Neutral,-0.024438
Instil  ( TIL )  Stock Rises More Than 20% in a Week: Here's Why,20240118T172800,https://www.zacks.com/stock/news/2212365/instil-til-stock-rises-more-than-20-in-a-week-heres-why,CTMX,0.472338,Neutral,0.037074
Is it a Good Idea to Invest in Intellia  ( NTLA )  Stock Now?,20240118T165000,https://www.zacks.com/stock/news/2212290/is-it-a-good-idea-to-invest-in-intellia-ntla-stock-now,CTMX,0.371523,Neutral,0.034133
Allakos  ( ALLK )  Plummets 60% on Ending Development of Lead Drug,20240117T171000,https://www.zacks.com/stock/news/2211650/allakos-allk-plummets-60-on-ending-development-of-lead-drug,CTMX,0.295867,Neutral,-0.024026
Aclaris  ( ACRS )  Stock Rises on Appointment of New Interim CEO,20240117T161400,https://www.zacks.com/stock/news/2211548/aclaris-acrs-stock-rises-on-appointment-of-new-interim-ceo,CTMX,0.392948,Neutral,0.032746
Reasons to Add Blueprint  ( BPMC )  Stock to Your Portfolio Now,20240116T165100,https://www.zacks.com/stock/news/2210923/reasons-to-add-blueprint-bpmc-stock-to-your-portfolio-now,CTMX,0.31282,Neutral,0.029893
Adaptimmune  ( ADAP )  Surges More Than 80% in a Month: Here's Why,20240116T161700,https://www.zacks.com/stock/news/2210881/adaptimmune-adap-surges-more-than-80-in-a-month-heres-why,CTMX,0.293038,Neutral,0.069295
Iovance  ( IOVA )  Surges More Than 150% in 3 Months: Here's Why,20240115T172700,https://www.zacks.com/stock/news/2210369/iovance-iova-surges-more-than-150-in-3-months-heres-why,CTMX,0.21193,Neutral,0.053496
Solid Biosciences  ( SLDB )  Rises 271% in 3 Months: Here's Why,20240115T151800,https://www.zacks.com/stock/news/2210246/solid-biosciences-sldb-rises-271-in-3-months-heres-why,CTMX,0.433523,Neutral,0.038038
"Beat the Market the Zacks Way: DaVita, Block, Home Depot in Focus",20240115T130600,https://www.zacks.com/stock/news/2210009/beat-the-market-the-zacks-way-davita-block-home-depot-in-focus,CTMX,0.065866,Somewhat-Bullish,0.312393
Emergent  ( EBS )  Gets $235.8M DoD Contract for Anthrax Vaccine,20240112T192000,https://www.zacks.com/stock/news/2209718/emergent-ebs-gets-2358m-dod-contract-for-anthrax-vaccine,CTMX,0.279653,Neutral,-0.022969
Amicus  ( FOLD )  Stock Rises More Than 25% in 3 Months: Here's Why,20240112T143100,https://www.zacks.com/stock/news/2209482/amicus-fold-stock-rises-more-than-25-in-3-months-heres-why,CTMX,0.381949,Neutral,0.032086
CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20240112T130000,https://www.benzinga.com/pressreleases/24/01/g36609305/cytomx-therapeutics-to-present-at-the-b-riley-securities-virtual-annual-oncology-conference,CTMX,0.28008,Neutral,0.032022
CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference,20240112T130000,https://www.globenewswire.com/news-release/2024/01/12/2808578/37704/en/CytomX-Therapeutics-to-Present-at-the-B-Riley-Securities-Virtual-Annual-Oncology-Conference.html,CTMX,0.209365,Neutral,-0.014718
Aclaris  ( ACRS )  Down 21% on Mixed Results From Eczema Study,20240111T164600,https://www.zacks.com/stock/news/2209029/aclaris-acrs-down-21-on-mixed-results-from-eczema-study,CTMX,0.23907,Neutral,-0.020236
Why Sarepta's  ( SRPT )  Stock Price Moved Up 17% on Tuesday,20240110T174900,https://www.zacks.com/stock/news/2208461/why-sareptas-srpt-stock-price-moved-up-17-on-tuesday,CTMX,0.282886,Neutral,-0.02757
"Moderna  ( MRNA )  Issues 2023 Preliminary Results, Stock Up 4%",20240109T181500,https://www.zacks.com/stock/news/2207654/moderna-mrna-issues-2023-preliminary-results-stock-up-4,CTMX,0.273807,Neutral,-0.022647
CytomX Therapeutics Outlines 2024 Company Priorities and Milestones - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20240104T130000,https://www.benzinga.com/pressreleases/24/01/g36488030/cytomx-therapeutics-outlines-2024-company-priorities-and-milestones,CTMX,0.126784,Neutral,0.038576
CytomX Therapeutics Outlines 2024 Company Priorities and Milestones,20240104T130000,https://www.globenewswire.com/news-release/2024/01/04/2803919/37704/en/CytomX-Therapeutics-Outlines-2024-Company-Priorities-and-Milestones.html,CTMX,0.111574,Neutral,0.072076
Why Moderna  ( MRNA )  Stock Price Was Up 13% on Tuesday,20240103T185600,https://www.zacks.com/stock/news/2205244/why-moderna-mrna-stock-price-was-up-13-on-tuesday,CTMX,0.222022,Neutral,0.086244
MeiraGTx  ( MGTX )  Stock Surges 35% in a Month: Here's Why,20240102T171700,https://www.zacks.com/stock/news/2204585/meiragtx-mgtx-stock-surges-35-in-a-month-heres-why,CTMX,0.289576,Neutral,0.07981
Bausch Health  ( BHC )  Ulcerative Colitis Drug Meets Primary Goal,20231222T152300,https://www.zacks.com/stock/news/2201653/bausch-health-bhc-ulcerative-colitis-drug-meets-primary-goal,CTMX,0.249106,Neutral,0.09766
CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference,20231221T130000,https://www.globenewswire.com/news-release/2023/12/21/2799945/37704/en/CytomX-Therapeutics-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html,CTMX,0.201523,Neutral,0.0
CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20231221T130000,https://www.benzinga.com/pressreleases/23/12/g36341721/cytomx-therapeutics-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference,CTMX,0.186738,Neutral,0.0
"Moderna  ( MRNA ) , Merck Start 2nd Late-Study on Cancer Therapy",20231212T181700,https://www.zacks.com/stock/news/2196987/moderna-mrna-merck-start-2nd-late-study-on-cancer-therapy,CTMX,0.29234,Neutral,0.075936
Sanofi  ( SNY )  Terminates Pompe Disease Deal as FTC Objects,20231212T142000,https://www.zacks.com/stock/news/2196713/sanofi-sny-terminates-pompe-disease-deal-as-ftc-objects,CTMX,0.273552,Neutral,0.074509
Merck's  ( MRK )  Keytruda-Lynparza Combo Fails Lung Cancer Study,20231208T164400,https://www.zacks.com/stock/news/2195640/mercks-mrk-keytruda-lynparza-combo-fails-lung-cancer-study,CTMX,0.300946,Neutral,0.077697
"Pfizer  ( PFE ) , Arvinas Post Upbeat Data From Breast Cancer Study",20231206T161800,https://www.zacks.com/stock/news/2194285/pfizer-pfe-arvinas-post-upbeat-data-from-breast-cancer-study,CTMX,0.318897,Neutral,0.083659
Alterity  ( ATHE )  Up on Preclinical Parkinson's Treatment Data,20231205T181900,https://www.zacks.com/stock/news/2193796/alterity-athe-up-on-preclinical-parkinsons-treatment-data,CTMX,0.318074,Neutral,0.078787
CRISPR  ( CRSP )  to Focus on Next-Generation CAR T Pipeline,20231205T181500,https://www.zacks.com/stock/news/2193794/crispr-crsp-to-focus-on-next-generation-car-t-pipeline,CTMX,0.233556,Neutral,0.065273
Vanda  ( VNDA )  Rises as FDA Accepts NDA for Gastroparesis Drug,20231205T141700,https://www.zacks.com/stock/news/2193518/vanda-vnda-rises-as-fda-accepts-nda-for-gastroparesis-drug,CTMX,0.34974,Neutral,0.047676
J&J's  ( JNJ )  Bladder Cancer Drug Gets FDA's Breakthrough Tag,20231205T124000,https://www.zacks.com/stock/news/2193403/jjs-jnj-bladder-cancer-drug-gets-fdas-breakthrough-tag,CTMX,0.302243,Neutral,0.082988
Apellis  ( APLS )  Rides on Syfovre to Fuel Growth Amid Rivalry,20231204T154500,https://www.zacks.com/stock/news/2193043/apellis-apls-rides-on-syfovre-to-fuel-growth-amid-rivalry,CTMX,0.330286,Neutral,0.045698
AstraZeneca  ( AZN )  to Discontinue Two Studies on Lokelma,20231201T162700,https://www.zacks.com/stock/news/2192314/astrazeneca-azn-to-discontinue-two-studies-on-lokelma,CTMX,0.443626,Neutral,0.056386
Annovis Bio  ( ANVS )  Stock Surges 38% in a Month: Here's Why,20231201T161200,https://www.zacks.com/stock/news/2192301/annovis-bio-anvs-stock-surges-38-in-a-month-heres-why,CTMX,0.235366,Neutral,0.069513
AbbVie  ( ABBV )  Posts Encouraging Data From Lung Cancer Study,20231130T165600,https://www.zacks.com/stock/news/2191706/abbvie-abbv-posts-encouraging-data-from-lung-cancer-study,CTMX,0.293741,Neutral,0.078444
FDA Accepts Karuna's  ( KRTX )  NDA Filing for Schizophrenia Drug,20231130T165400,https://www.zacks.com/stock/news/2191704/fda-accepts-karunas-krtx-nda-filing-for-schizophrenia-drug,CTMX,0.247334,Neutral,0.064494
Adaptimmune  ( ADAP )  Rises as GSK Transfers T-Cell Therapy IND,20231130T155200,https://www.zacks.com/stock/news/2191582/adaptimmune-adap-rises-as-gsk-transfers-t-cell-therapy-ind,CTMX,0.448842,Neutral,0.062924
Emergent  ( EBS )  Gets $75M BARDA Contract for Anthrax Vaccine,20231129T165600,https://www.zacks.com/stock/news/2191044/emergent-ebs-gets-75m-barda-contract-for-anthrax-vaccine,CTMX,0.248851,Neutral,0.066696
Immunovant  ( IMVT )  Up on Positive Initial IMVT-1402 MAD Study Data,20231129T152200,https://www.zacks.com/stock/news/2190953/immunovant-imvt-up-on-positive-initial-imvt-1402-mad-study-data,CTMX,0.381949,Neutral,0.050853
SpringWorks  ( SWTX )  Rises on FDA Nod for Desmoid Tumor Drug,20231129T152000,https://www.zacks.com/stock/news/2190950/springworks-swtx-rises-on-fda-nod-for-desmoid-tumor-drug,CTMX,0.419153,Neutral,0.054286
GSK: 3 Pharma Stocks on the Rise - It's Time to Buy Now,20231128T164445,https://stocknews.com/news/gsk-eton-ctmx-arwr-srra-3-pharma-stocks-on-the-rise-its-time-to/,CTMX,0.218598,Neutral,0.142313
Xenon  ( XENE )  Up on Top-Line Data From MDD Drug Phase II Study,20231128T161700,https://www.zacks.com/stock/news/2190420/xenon-xene-up-on-top-line-data-from-mdd-drug-phase-ii-study,CTMX,0.369685,Neutral,0.049662
TC BioPharm  ( TCBP )  Falls Despite FDA Clearing IND for AML Drug,20231128T160500,https://www.zacks.com/stock/news/2190409/tc-biopharm-tcbp-falls-despite-fda-clearing-ind-for-aml-drug,CTMX,0.42503,Neutral,0.054804
GSK's Blenrep Combo Meets PFS Endpoint in Head-to-Head Study,20231127T182200,https://www.zacks.com/stock/news/2189947/gsks-blenrep-combo-meets-pfs-endpoint-in-head-to-head-study,CTMX,0.323927,Neutral,-0.03312
CRISPR  ( CRSP )  Rises More Than 40% in Past 3 Months: Here's Why,20231124T165000,https://www.zacks.com/stock/news/2189212/crispr-crsp-rises-more-than-40-in-past-3-months-heres-why,CTMX,0.359881,Neutral,0.051295
Vertex  ( VRTX )  Gets EU Nod for Kaftrio Use in 2-5 Year Kids,20231124T164800,https://www.zacks.com/stock/news/2189211/vertex-vrtx-gets-eu-nod-for-kaftrio-use-in-2-5-year-kids,CTMX,0.400265,Neutral,0.055432
Freeline  ( FRLN )  Shares Rise on Merger Agreement With Syncona,20231123T160300,https://www.zacks.com/stock/news/2188517/freeline-frln-shares-rise-on-merger-agreement-with-syncona,CTMX,0.392948,Neutral,0.051882
"Immix  ( IMMX )  CAR-T Therapy IND Cleared by FDA, Stock Down",20231122T161000,https://www.zacks.com/stock/news/2187964/immix-immx-car-t-therapy-ind-cleared-by-fda-stock-down,CTMX,0.401331,Neutral,0.052647
Here's Why You May Invest in Puma Biotechnology  ( PBYI )  Stock,20231120T164700,https://www.zacks.com/stock/news/2186786/heres-why-you-may-invest-in-puma-biotechnology-pbyi-stock,CTMX,0.323078,Neutral,-0.007122
CytomX Therapeutics  ( CTMX )  Upgraded to Strong Buy: What Does It Mean for the Stock?,20231113T170005,https://www.zacks.com/stock/news/2183493/cytomx-therapeutics-ctmx-upgraded-to-strong-buy-what-does-it-mean-for-the-stock,CTMX,0.364275,Bullish,0.355061
CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update,20231107T211500,https://www.globenewswire.com/news-release/2023/11/07/2775653/37704/en/CytomX-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Update.html,CTMX,0.107575,Neutral,0.029993
CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20231107T211500,https://www.benzinga.com/pressreleases/23/11/g35658764/cytomx-therapeutics-reports-third-quarter-2023-financial-results-and-provides-business-update,CTMX,0.104911,Neutral,0.014344
CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b at the SITC 2023 Annual Meeting - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20231030T120000,https://www.benzinga.com/pressreleases/23/10/g35487786/cytomx-therapeutics-to-present-preclinical-data-for-conditionally-activated-interferon-alpha-2b-at,CTMX,0.215319,Neutral,0.005188
CytomX Therapeutics Presents Preclinical Profile of EpCAM-directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference,20231018T203000,https://www.globenewswire.com/news-release/2023/10/18/2762767/37704/en/CytomX-Therapeutics-Presents-Preclinical-Profile-of-EpCAM-directed-Antibody-Drug-Conjugate-CX-2051-at-2023-World-ADC-Conference.html,CTMX,0.183059,Neutral,-0.059197
"Triple-Negative Breast Cancer Market to Accelerate Substantially During the Forecast Period  ( 2023-2032 ) , Examines DelveInsight | Key Companies to Watch - Roche, AbbVie, AstraZeneca, BeiGene, GlaxoSmithKline, Genentech, Eli Lilly, Novartis",20230906T210100,https://www.prnewswire.com/news-releases/triple-negative-breast-cancer-market-to-accelerate-substantially-during-the-forecast-period-20232032-examines-delveinsight--key-companies-to-watch---roche-abbvie-astrazeneca-beigene-glaxosmithkline-genentech-eli-lilly--301918858.html,CTMX,0.022494,Neutral,0.023078
"CytomX Therapeutics  ( CTMX )  Loses -13.45% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner",20230825T133505,https://www.zacks.com/stock/news/2140745/cytomx-therapeutics-ctmx-loses--1345-in-4-weeks-heres-why-a-trend-reversal-may-be-around-the-corner,CTMX,0.48028,Somewhat-Bullish,0.220312
CytomX Therapeutics to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20230810T200500,https://www.benzinga.com/pressreleases/23/08/g33723142/cytomx-therapeutics-to-present-at-the-h-c-wainwright-immune-cell-engager-virtual-conference,CTMX,0.272788,Neutral,0.13455
"CytomX Therapeutics  ( NASDAQ:CTMX )  Raised to ""Buy"" at StockNews.com",20230810T085244,https://www.defenseworld.net/2023/08/10/cytomx-therapeutics-nasdaqctmx-raised-to-buy-at-stocknews-com.html,CTMX,0.80274,Somewhat-Bullish,0.199957
"CytomX Therapeutics  ( CTMX )  Reports Q2 Loss, Tops Revenue Estimates",20230808T213014,https://www.zacks.com/stock/news/2133884/cytomx-therapeutics-ctmx-reports-q2-loss-tops-revenue-estimates,CTMX,0.396052,Somewhat-Bullish,0.171518
CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update,20230808T201500,https://www.globenewswire.com/news-release/2023/08/08/2721181/37704/en/CytomX-Therapeutics-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Business-Update.html,CTMX,0.089595,Neutral,0.089007
CytomX Therapeutics  ( NASDAQ:CTMX )  Downgraded by StockNews.com to Hold,20230806T091911,https://www.defenseworld.net/2023/08/06/cytomx-therapeutics-nasdaqctmx-downgraded-by-stocknews-com-to-hold.html,CTMX,0.809093,Somewhat-Bullish,0.338803
CytomX Therapeutics  ( NASDAQ:CTMX )  Stock Rating Lowered by StockNews.com,20230804T062443,https://www.defenseworld.net/2023/08/04/cytomx-therapeutics-nasdaqctmx-stock-rating-lowered-by-stocknews-com.html,CTMX,0.779232,Somewhat-Bullish,0.231266
Exelixis  ( EXEL )  Tops Q2 Earnings and Revenue Estimates,20230801T215511,https://www.zacks.com/stock/news/2130720/exelixis-exel-tops-q2-earnings-and-revenue-estimates,CTMX,0.20997,Neutral,0.0
Why Is CytomX Therapeutics  ( CTMX )  Stock Shooting Higher Today - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20230630T152637,https://www.benzinga.com/markets/equities/23/06/33079372/why-is-cytomx-therapeutics-stock-shooting-higher-today,CTMX,0.517168,Neutral,-0.032618
Zymeworks Appoints New Director - Zymeworks  ( NASDAQ:ZYME ) ,20230629T200500,https://www.benzinga.com/pressreleases/23/06/g33066902/zymeworks-appoints-new-director,CTMX,0.032294,Neutral,0.079842
"CytomX Therapeutics  ( CTMX )  Reports Q1 Loss, Tops Revenue Estimates",20230509T213513,https://www.zacks.com/stock/news/2092733/cytomx-therapeutics-ctmx-reports-q1-loss-tops-revenue-estimates,CTMX,0.404563,Neutral,0.098379
"Codexis  ( CDXS )  Reports Q1 Loss, Lags Revenue Estimates",20230504T230514,https://www.zacks.com/stock/news/2090536/codexis-cdxs-reports-q1-loss-lags-revenue-estimates,CTMX,0.207571,Neutral,0.0
"Certara, Inc.  ( CERT )  Earnings Expected to Grow: What to Know Ahead of Next Week's Release",20230501T140101,https://www.zacks.com/stock/news/2087492/certara-inc-cert-earnings-expected-to-grow-what-to-know-ahead-of-next-weeks-release,CTMX,0.175859,Neutral,-0.002859
Will CytomX Therapeutics  ( CTMX )  Report Negative Q1 Earnings? What You Should Know,20230427T140320,https://www.zacks.com/stock/news/2085976/will-cytomx-therapeutics-ctmx-report-negative-q1-earnings-what-you-should-know,CTMX,0.258808,Neutral,0.02171
CytomX Therapeutics  ( NASDAQ:CTMX )  Rating Increased to Hold at StockNews.com,20230401T052648,https://www.defenseworld.net/2023/04/01/cytomx-therapeutics-nasdaqctmx-rating-increased-to-hold-at-stocknews-com.html,CTMX,0.875421,Bullish,0.411224
"Walgreens, McCormick rise; Invesco Mortgage, CytomX fall",20230328T201541,https://apnews.com/article/financial-markets-stocks-wall-street-62e81c0ad79234af9aca55348dd7426e,CTMX,0.31482,Neutral,0.0
Why CytomX Therapeutics  ( CTMX )  Shares Are Falling Today - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20230328T153514,https://www.benzinga.com/general/biotech/23/03/31531824/abbvie-walks-away-from-cytomx-partnership-but-garnering-attention-of-big-pharma-partners,CTMX,0.405651,Somewhat-Bullish,0.15048
"CytomX Therapeutics  ( CTMX )  Reports Q4 Loss, Lags Revenue Estimates",20230327T213504,https://www.zacks.com/stock/news/2070995/cytomx-therapeutics-ctmx-reports-q4-loss-lags-revenue-estimates,CTMX,0.397098,Neutral,0.108321
CytomX Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update,20230327T201500,https://www.globenewswire.com/news-release/2023/03/27/2635245/37704/en/CytomX-Therapeutics-Reports-Full-Year-2022-Financial-Results-and-Provides-Business-Update.html,CTMX,0.094887,Neutral,0.054027
"Why Motorsport Games Shares Are Trading Lower By Over 10%; Here Are 20 Stocks Moving Premarket - Berkshire Grey  ( NASDAQ:BGRY ) , Allarity Therapeutics  ( NASDAQ:ALLR ) ",20230327T115915,https://www.benzinga.com/news/23/03/31508672/why-motorsport-games-shares-are-trading-lower-by-over-10-here-are-20-stocks-moving-premarket,CTMX,0.219477,Neutral,0.0
StockNews.com CytomX Therapeutics  ( NASDAQ:CTMX )  to be Sold,20230325T194117,https://beststocks.com/stocknews-com-cytomx-therapeutics-nasdaqctmx-to/,CTMX,0.849882,Somewhat-Bullish,0.166042
CytomX Therapeutics  ( NASDAQ:CTMX )  Rating Lowered to Sell at StockNews.com,20230324T052641,https://www.defenseworld.net/2023/03/24/cytomx-therapeutics-nasdaqctmx-rating-lowered-to-sell-at-stocknews-com.html,CTMX,0.871557,Bullish,0.442273
"CytomX Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 27, 2023 - CytomX Therapeutics  ( NASDAQ:CTMX ) ",20230322T232333,https://www.benzinga.com/pressreleases/23/03/g31466980/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-27-2023,CTMX,0.33628,Neutral,-0.051278
"CytomX Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 27, 2023",20230322T232300,https://www.globenewswire.com/news-release/2023/03/22/2632792/37704/en/CytomX-Therapeutics-to-Report-Fourth-Quarter-and-Full-Year-2022-Financial-Results-on-March-27-2023.html,CTMX,0.273807,Neutral,0.0
"Castle Biosciences, Inc.  ( CSTL )  Reports Q4 Loss, Tops Revenue Estimates",20230301T003509,https://www.zacks.com/stock/news/2060093/castle-biosciences-inc-cstl-reports-q4-loss-tops-revenue-estimates,CTMX,0.206392,Neutral,0.0
CytomX Therapeutics to Present at Upcoming March Investor Conferences - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20230228T210500,https://www.benzinga.com/pressreleases/23/02/g31103016/cytomx-therapeutics-to-present-at-upcoming-march-investor-conferences,CTMX,0.245339,Neutral,0.0
"NeoGenomics  ( NEO )  Reports Q4 Loss, Tops Revenue Estimates",20230223T150505,https://www.zacks.com/stock/news/2058195/neogenomics-neo-reports-q4-loss-tops-revenue-estimates,CTMX,0.20997,Neutral,0.0
"Beyond Air, Inc.  ( XAIR )  Reports Q3 Loss, Lags Revenue Estimates",20230209T222510,https://www.zacks.com/stock/news/2052563/beyond-air-inc-xair-reports-q3-loss-lags-revenue-estimates,CTMX,0.212425,Neutral,0.0
Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results,20230203T113000,https://www.globenewswire.com/news-release/2023/02/03/2601193/0/en/Regeneron-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-and-Operating-Results.html,CTMX,0.010985,Neutral,0.076094
CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific  ( TCB )  Collaboration with Astellas,20230126T120000,https://www.globenewswire.com/news-release/2023/01/26/2595893/37704/en/CytomX-Therapeutics-Announces-Milestone-Achievement-in-Probody-T-Cell-Engaging-Bispecific-TCB-Collaboration-with-Astellas.html,CTMX,0.169437,Somewhat-Bullish,0.207431
CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Investor Conference,20230117T210500,https://www.benzinga.com/pressreleases/23/01/g30450762/cytomx-therapeutics-to-present-at-the-b-riley-securities-virtual-annual-oncology-investor-conferen,CTMX,0.157483,Neutral,-0.011986
"5 Most Expensive Health Care Stocks You Should Worry About - Alterity Therapeutics  ( NASDAQ:ATHE ) , Cellectis  ( NASDAQ:CLLS ) ",20230112T140141,https://www.benzinga.com/news/23/01/30389571/5-most-expensive-health-care-stocks-you-should-worry-about,CTMX,0.360752,Neutral,-0.053615
"Tesla, Moderna And These 2 Stocks Insiders Are Selling - Albemarle  ( NYSE:ALB ) , Hewlett Packard  ( NYSE:HPE ) ",20230109T140336,https://www.benzinga.com/news/23/01/30332910/tesla-moderna-and-these-2-stocks-insiders-are-selling,CTMX,0.085324,Somewhat-Bullish,0.186363
AbbVie cuts earnings forecast due to milestone payments,20230106T235200,https://www.marketwatch.com/story/abbvie-cuts-earnings-forecast-due-to-milestone-payments-11673048665,CTMX,0.261117,Somewhat-Bullish,0.155819
CytomX  ( CTMX )  Up 55% on Strategic Partnership With Moderna,20230106T184600,https://www.zacks.com/stock/news/2036409/cytomx-ctmx-up-55-on-strategic-partnership-with-moderna,CTMX,0.381755,Neutral,0.079226
Why CytomX Therapeutics  ( CTMX )  Shares Are Soaring Today - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20230106T153029,https://www.benzinga.com/general/biotech/23/01/30310896/cytomx-shares-move-higher-on-collaborating-pact-with-this-famed-covid-19-vaccine-maker,CTMX,0.546745,Bullish,0.508679
"Moderna, CytomX to collaborate on mRNA-based therapies",20230105T213200,https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-cytomx-announce-mrna-collaboration-2023-01-05/,CTMX,0.295867,Somewhat-Bullish,0.177099
"CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics - CytomX Therapeutics  ( NASDAQ:CTMX ) , Moderna  ( NASDAQ:MRNA ) ",20230105T210500,https://www.benzinga.com/pressreleases/23/01/g30301606/cytomx-and-moderna-announce-strategic-research-collaboration-for-mrna-based-conditionally-activate,CTMX,0.067095,Neutral,0.06913
"CytomX Therapeutics to Outline 2023 Company Priorities and Provide Pipeline Update on January 5, 2023",20221222T220000,https://www.globenewswire.com/news-release/2022/12/22/2578939/37704/en/CytomX-Therapeutics-to-Outline-2023-Company-Priorities-and-Provide-Pipeline-Update-on-January-5-2023.html,CTMX,0.17715,Neutral,0.0
CytomX Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference,20221220T220000,https://www.globenewswire.com/news-release/2022/12/20/2577524/37704/en/CytomX-Therapeutics-to-Present-at-the-41st-Annual-J-P-Morgan-Healthcare-Conference.html,CTMX,0.163909,Neutral,0.0
CytomX Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20221220T220000,https://www.benzinga.com/pressreleases/22/12/g30153373/cytomx-therapeutics-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference,CTMX,0.153961,Neutral,0.0
CytomX Therapeutics to Present Phase 2 Data for Praluzatamab Ravtansine  ( CX-2009 )  in Patients with Advanced Breast Cancer at the San Antonio Breast Cancer Symposium - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20221207T213000,https://www.benzinga.com/pressreleases/22/12/g29999143/cytomx-therapeutics-to-present-phase-2-data-for-praluzatamab-ravtansine-cx-2009-in-patients-with-a,CTMX,0.238718,Neutral,-0.113579
CytomX Therapeutics to Present Phase 2 Data for Praluzatamab Ravtansine  ( CX-2009 )  in Patients with Advanced Breast Cancer at the San Antonio Breast Cancer Symposium,20221207T213000,https://www.globenewswire.com/news-release/2022/12/07/2569745/37704/en/CytomX-Therapeutics-to-Present-Phase-2-Data-for-Praluzatamab-Ravtansine-CX-2009-in-Patients-with-Advanced-Breast-Cancer-at-the-San-Antonio-Breast-Cancer-Symposium.html,CTMX,0.104228,Somewhat-Bearish,-0.162137
"Biotech Stock Roundup: CTMX Surges on REGN's Deal, APLS Up on Regulatory Update",20221123T171800,https://www.zacks.com/stock/news/2021539/biotech-stock-roundup-ctmx-surges-on-regns-deal-apls-up-on-regulatory-update,CTMX,0.214937,Somewhat-Bullish,0.209327
Best Penny Stocks To Buy Now? 5 Biotech Stocks To Watch This Week,20221121T175936,https://pennystocks.com/featured/2022/11/21/best-penny-stocks-to-buy-now-5-biotech-stocks-to-watch-this-week/,CTMX,0.070002,Neutral,0.041554
CytomX Therapeutics  ( NASDAQ:CTMX )  Upgraded to Hold by StockNews.com,20221119T082444,https://www.etfdailynews.com/2022/11/19/cytomx-therapeutics-nasdaqctmx-upgraded-to-hold-by-stocknews-com/,CTMX,0.854923,Bullish,0.359687
CytomX  ( CTMX )  Stock Surges on Oncology Deal With Regeneron,20221118T181800,https://www.zacks.com/stock/news/2020092/cytomx-ctmx-stock-surges-on-oncology-deal-with-regeneron,CTMX,0.220809,Somewhat-Bullish,0.254083
"Stocks making the biggest moves midday: Bath & Body Works, Norwegian Cruise Line, Macy's and more",20221117T182031,https://www.cnbc.com/2022/11/17/stocks-making-the-biggest-moves-midday-bath-body-works-norwegian-cruise-line-macys-and-more.html,CTMX,0.093653,Neutral,0.0
Why CytomX  ( CTMX )  Shares Are Jumping Today - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,20221117T161402,https://www.benzinga.com/general/biotech/22/11/29766139/cytomx-shares-jump-after-cancer-therapy-pact-with-pharma-major-regeneron,CTMX,0.703273,Somewhat-Bullish,0.328014
"Heska To $165? Plus BTIG Cuts PT On This Stock By 67% - CytomX Therapeutics  ( NASDAQ:CTMX ) , Elanco Animal Health  ( NYSE:ELAN ) ",20221114T132114,https://www.benzinga.com/news/22/11/29699762/heska-to-165-plus-btig-cuts-pt-on-this-stock-by-67,CTMX,0.491878,Neutral,0.0382
CytomX Therapeutics  ( NASDAQ:CTMX )  Stock Rating Lowered by StockNews.com,20221113T063044,https://www.etfdailynews.com/2022/11/13/cytomx-therapeutics-nasdaqctmx-stock-rating-lowered-by-stocknews-com/,CTMX,0.876064,Neutral,0.078758
"CytomX Therapeutics  ( CTMX )  Reports Q3 Loss, Misses Revenue Estimates",20221108T223519,https://www.zacks.com/stock/news/2015670/cytomx-therapeutics-ctmx-reports-q3-loss-misses-revenue-estimates,CTMX,0.40348,Neutral,-0.033108
CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b  ( CX-801 )  at the SITC 2022 Annual Meeting,20221107T211500,https://www.globenewswire.com/news-release/2022/11/07/2550277/37704/en/CytomX-Therapeutics-to-Present-Preclinical-Data-for-Conditionally-Activated-Interferon-Alpha-2b-CX-801-at-the-SITC-2022-Annual-Meeting.html,CTMX,0.140076,Neutral,0.015432
CytomX Therapeutics to Present at Upcoming November Investor Conferences,20221102T201500,https://www.globenewswire.com/news-release/2022/11/02/2547066/37704/en/CytomX-Therapeutics-to-Present-at-Upcoming-November-Investor-Conferences.html,CTMX,0.247838,Neutral,0.0
CytomX Therapeutics to Present at Upcoming November Investor Conferences - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20221102T201500,https://www.benzinga.com/pressreleases/22/11/g29532629/cytomx-therapeutics-to-present-at-upcoming-november-investor-conferences,CTMX,0.213674,Neutral,0.0
"Travere Therapeutics  ( TVTX )  Reports Q3 Loss, Tops Revenue Estimates",20221027T211512,https://www.zacks.com/stock/news/1998898/travere-therapeutics-tvtx-reports-q3-loss-tops-revenue-estimates,CTMX,0.210579,Neutral,0.0
CytomX Therapeutics Announces Phase 1 Data Update for anti-CTLA-4 Probody® Therapeutic BMS-986249,20220912T120000,https://www.globenewswire.com/news-release/2022/09/12/2513952/37704/en/CytomX-Therapeutics-Announces-Phase-1-Data-Update-for-anti-CTLA-4-Probody-Therapeutic-BMS-986249.html,CTMX,0.152499,Neutral,-0.025944
CytomX Therapeutics Presents Overview of Conditionally-Activated Antibody-Drug Conjugate  ( ADC )  Programs Including Next Generation EpCAM-Targeting CX-2051,20220907T220500,https://www.globenewswire.com/news-release/2022/09/07/2512047/37704/en/CytomX-Therapeutics-Presents-Overview-of-Conditionally-Activated-Antibody-Drug-Conjugate-ADC-Programs-Including-Next-Generation-EpCAM-Targeting-CX-2051.html,CTMX,0.1185,Neutral,-0.046001
CytomX Therapeutics  ( NASDAQ:CTMX )  Rating Increased to Hold at StockNews.com,20220807T054641,https://www.defenseworld.net/2022/08/07/cytomx-therapeutics-nasdaqctmx-rating-increased-to-hold-at-stocknews-com.html,CTMX,0.818658,Somewhat-Bullish,0.200016
CytomX Therapeutics  ( CTMX )  Q2 2022 Earnings Call Transcript,20220805T123040,https://www.fool.com/earnings/call-transcripts/2022/08/05/cytomx-therapeutics-ctmx-q2-2022-earnings-call-tra/,CTMX,0.011502,Somewhat-Bullish,0.285902
CytomX Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update,20220804T201500,https://www.globenewswire.com/news-release/2022/08/04/2492842/37704/en/CytomX-Therapeutics-Reports-Second-Quarter-2022-Financial-Results-and-Provides-Business-Update.html,CTMX,0.078805,Neutral,0.018531
CytomX Therapeutics to Present at Upcoming Virtual August Investor Conferences,20220803T120000,https://www.globenewswire.com/news-release/2022/08/03/2491316/37704/en/CytomX-Therapeutics-to-Present-at-Upcoming-Virtual-August-Investor-Conferences.html,CTMX,0.19117,Neutral,0.0
ANI Pharmaceuticals  ( ANIP )  Expected to Beat Earnings Estimates: Can the Stock Move Higher?,20220801T140108,https://www.zacks.com/stock/news/1961336/ani-pharmaceuticals-anip-expected-to-beat-earnings-estimates-can-the-stock-move-higher,CTMX,0.173958,Neutral,0.078049
CytomX Therapeutics  ( CTMX )  Expected to Beat Earnings Estimates: Can the Stock Move Higher?,20220728T140237,https://www.zacks.com/stock/news/1959762/cytomx-therapeutics-ctmx-expected-to-beat-earnings-estimates-can-the-stock-move-higher,CTMX,0.257895,Neutral,0.144261
"The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures",20220714T130111,https://www.benzinga.com/general/biotech/22/07/28062629/the-daily-biotech-pulse-much-awaited-fda-nod-for-novavaxs-covid-19-shot-dsmb-suggests-contrafect-,CTMX,0.114137,Neutral,0.116579
DMAC: 4 Downgraded Stocks to Stay Away From in July,20220708T162339,https://stocknews.com/news/dmac-ctmx-cash-lob-4-downgraded-stocks-to-stay-away-from-in-july/,CTMX,0.181409,Neutral,-0.024422
Nasdaq Surges 250 Points; Crude Oil Rises Sharply,20220707T190149,https://www.benzinga.com/news/earnings/22/07/27992230/nasdaq-surges-250-points-crude-oil-rises-sharply,CTMX,0.174377,Neutral,0.003563
Dow Jumps More Than 200 Points; Samsung Sees This Much Surge In Quarterly Revenue,20220707T161116,https://www.benzinga.com/news/earnings/22/07/27990031/dow-jumps-more-than-200-points-samsung-sees-this-much-surge-in-quarterly-revenue,CTMX,0.167671,Neutral,0.005113
"The Daily Biotech Pulse: Merck's Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 Pill",20220707T140337,https://www.benzinga.com/general/biotech/22/07/27983728/the-daily-biotech-pulse-mercks-potential-seagen-buyout-expected-in-weeks-fda-holds-diamedicas-str,CTMX,0.130358,Neutral,0.003271
CytomX's Breast Cancer Candidate Meets Primary Goal Of Objective Response Rate,20220707T101529,https://www.benzinga.com/general/biotech/22/07/27982198/cytomxs-breast-cancer-candidate-meets-primary-goal-of-objective-response-rate,CTMX,0.465478,Neutral,0.001653
U.S. Stock Futures Edge Higher After Fed Minutes,20220707T090756,https://www.benzinga.com/news/earnings/22/07/27982324/u-s-stock-futures-edge-higher-after-fed-minutes,CTMX,0.189175,Neutral,0.00969
CytomX Therapeutics Announces Phase 2 Results for Praluzatamab Ravtansine in Breast Cancer,20220706T200500,https://www.globenewswire.com/news-release/2022/07/06/2475436/37704/en/CytomX-Therapeutics-Announces-Phase-2-Results-for-Praluzatamab-Ravtansine-in-Breast-Cancer.html,CTMX,0.082977,Neutral,0.000161
NeoGenomics  ( NEO )  Surges 6.4%: Is This an Indication of Further Gains?,20220627T123300,https://www.zacks.com/stock/news/1944243/neogenomics-neo-surges-64-is-this-an-indication-of-further-gains,CTMX,0.482078,Neutral,0.001978
"Aptose Appoints Fletcher Payne as Senior Vice President, Chief Financial Officer",20220627T121256,https://investingnews.com/aptose-appoints-fletcher-payne-as-senior-vice-president-chief-financial-officer/,CTMX,0.039438,Neutral,0.008323
"Aptose Appoints Fletcher Payne as Senior Vice President, Chief Financial Officer",20220627T113000,https://www.globenewswire.com/news-release/2022/06/27/2469416/35575/en/Aptose-Appoints-Fletcher-Payne-as-Senior-Vice-President-Chief-Financial-Officer.html,CTMX,0.038906,Neutral,0.008323
"CytomX Therapeutics  ( NASDAQ:CTMX )  Lowered to ""Sell"" at StockNews.com",20220527T052252,https://www.etfdailynews.com/2022/05/27/cytomx-therapeutics-nasdaqctmx-lowered-to-sell-at-stocknews-com/,CTMX,0.835236,Neutral,-0.012341
CytomX Therapeutics Initiates Dosing in Early-Stage Study Of Solid Tumor Settings,20220526T141813,https://www.benzinga.com/general/biotech/22/05/27417467/cytomx-therapeutics-initiates-dosing-in-early-stage-study-of-solid-tumor-settings,CTMX,0.586747,Neutral,0.014665
StockNews.com Downgrades CytomX Therapeutics  ( NASDAQ:CTMX )  to Sell,20220512T131241,https://www.defenseworld.net/2022/05/12/stocknews-com-downgrades-cytomx-therapeutics-nasdaqctmx-to-sell.html,CTMX,0.820106,Neutral,0.007376
CytomX Therapeutics  ( CTMX )  Q1 2022 Earnings Call Transcript,20220507T023041,https://www.fool.com/earnings/call-transcripts/2022/05/06/cytomx-therapeutics-ctmx-q1-2022-earnings-call-tra/,CTMX,0.007054,Bullish,0.936475
"CytomX Therapeutics  ( CTMX )  Reports Q1 Loss, Lags Revenue Estimates",20220505T222514,https://www.zacks.com/stock/news/1917319/cytomx-therapeutics-ctmx-reports-q1-loss-lags-revenue-estimates,CTMX,0.371062,Neutral,-0.083067
CytomX Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update,20220505T201500,https://www.globenewswire.com/news-release/2022/05/05/2437387/37704/en/CytomX-Therapeutics-Reports-First-Quarter-2022-Financial-Results-and-Provides-Business-Update.html,CTMX,0.081097,Neutral,0.133562
"Earnings Scheduled For May 5, 2022",20220505T084322,https://www.benzinga.com/news/earnings/22/05/27012606/earnings-scheduled-for-may-5-2022,CTMX,0.009774,Neutral,-0.043899
"CytomX Therapeutics to Report First Quarter 2022 Financial Results on May 5, 2022",20220428T120000,https://www.globenewswire.com/news-release/2022/04/28/2431297/37704/en/CytomX-Therapeutics-to-Report-First-Quarter-2022-Financial-Results-on-May-5-2022.html,CTMX,0.258991,Neutral,0.011355
CytomX Therapeutics  ( NASDAQ:CTMX )  Stock Rating Upgraded by StockNews.com,20220428T084645,https://www.defenseworld.net/2022/04/28/cytomx-therapeutics-nasdaqctmx-stock-rating-upgraded-by-stocknews-com.html,CTMX,0.825258,Neutral,0.00861
Stocks That Hit 52-Week Lows On Wednesday,20220420T161438,https://www.benzinga.com/news/22/04/26717868/stocks-that-hit-52-week-lows-on-wednesday,CTMX,0.015214,Neutral,-0.036665
Stocks That Hit 52-Week Lows On Tuesday,20220419T153817,https://www.benzinga.com/news/22/04/26693085/stocks-that-hit-52-week-lows-on-tuesday,CTMX,0.009731,Neutral,0.002419
"CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of Directors",20220414T201500,https://www.benzinga.com/pressreleases/22/04/g26646216/cytomx-therapeutics-announces-retirement-of-john-a-scarlett-m-d-from-board-of-directors,CTMX,0.319311,Neutral,0.145929
"CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of Directors",20220414T201500,https://www.globenewswire.com/news-release/2022/04/14/2423090/37704/en/CytomX-Therapeutics-Announces-Retirement-of-John-A-Scarlett-M-D-from-Board-of-Directors.html,CTMX,0.141851,Neutral,0.00377
Stocks That Hit 52-Week Lows On Friday,20220325T160550,https://www.benzinga.com/news/22/03/26299843/stocks-that-hit-52-week-lows-on-friday,CTMX,0.013769,Somewhat-Bearish,-0.268586
CytomX Therapeutics Announces Retirement of Frederick W. Gluck from Board of Directors,20220323T201500,https://www.benzinga.com/pressreleases/22/03/g26266130/cytomx-therapeutics-announces-retirement-of-frederick-w-gluck-from-board-of-directors,CTMX,0.302951,Somewhat-Bullish,0.154043
CytomX Therapeutics Announces Retirement of Frederick W. Gluck from Board of Directors,20220323T201500,https://www.globenewswire.com/news-release/2022/03/23/2408989/37704/en/CytomX-Therapeutics-Announces-Retirement-of-Frederick-W-Gluck-from-Board-of-Directors.html,CTMX,0.270598,Neutral,0.003956
